利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

65 条记录 (耗时 0.018 秒)

    Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
    3.
    发明授权
    Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms 有权
    三药治疗麻醉和酒精戒断症状

    公开(公告)号：US06503950B1

    公开(公告)日：2003-01-07

    申请号：US09634555

    申请日：2000-08-08

    申请人： David M. Ockert

    发明人： David M. Ockert

    IPC分类号： A61K31165

    CPC分类号： A61K31/522 ,  A61K31/135 ,  A61K31/137 ,  A61K31/155 ,  A61K31/165 ,  A61K31/192 ,  A61K31/195 ,  A61K31/415 ,  A61K31/4168 ,  A61K31/421 ,  A61K31/438 ,  A61K31/4458 ,  A61K31/495 ,  A61K31/55 ,  A61K31/5513 ,  Y10S514/811 ,  A61K2300/00

    摘要： A triple drug, pharmaceutical kit, composition, and method of treatment containing a combination of effective amounts of at least one anxiolytic agent, at least one centrally acting alpha antiadrenergic agent, and at least one central nervous system stimulant for the reduction or prevention of alcohol and narcotic withdrawal side effects of dizziness, drowsiness, depression, lethargy, orthostatic hypotension, weakness in the extremities, and difficulty in being mobile, caused by therapeutic agents utilized for the treatment of alcohol or narcotic withdrawal symptoms in patients overcoming alcohol or narcotic addiction.

    摘要翻译： 三重药物，药物试剂盒，组合物和治疗方法，其含有有效量的至少一种抗焦虑剂，至少一种中枢作用的α抗肾上腺作用剂和至少一种用于还原或预防酒精的中枢神经系统兴奋剂的组合 以及用于治疗酒精或麻醉成瘾患者的酒精或麻醉戒断症状的治疗剂引起的眩晕，嗜睡，抑郁，嗜睡，直立性低血压，四肢无力以及难以移动的麻醉戒断副作用。

    Inhibitors of transcription factor-NF-&kgr;B
    4.
    发明授权
    Inhibitors of transcription factor-NF-&kgr;B 失效
    转录因子NF-κB的抑制剂

    公开(公告)号：US06492425B1

    公开(公告)日：2002-12-10

    申请号：US09720018

    申请日：2000-12-19

    申请人： James F. Callahan ,  Marie C. Chabot-Fletcher

    发明人： James F. Callahan ,  Marie C. Chabot-Fletcher

    IPC分类号： A61K31165

    CPC分类号： A61K31/165 ,  C07C235/64

    摘要： The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-&kgr;B, and methods for treating diseases in which activation of NF-&kgr;B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-&kgr;B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

    摘要翻译： 本发明提供转录因子NF-κB的水杨酰苯胺抑制剂的药物组合物，以及涉及NF-κB活化的疾病的治疗方法。 更具体地，本发明提供了治疗与NF-κB活化相关的各种疾病的方法，包括炎症性疾病; 特别是类风湿关节炎，炎性肠病和哮喘; 皮肤病，包括牛皮癣和特应性皮炎; 自身免疫性疾病; 组织和器官排斥反应; 阿尔茨海默氏病; 行程; 动脉粥样硬化 再狭窄; 癌症包括霍奇金病; 某些病毒感染，包括艾滋病; 骨关节炎 骨质疏松症 通过向有需要的患者施用本发明的化合物来治疗共济失调症。

    Brain targeted low molecular weight hydrophobic antioxidant compounds
    6.
    发明授权
    Brain targeted low molecular weight hydrophobic antioxidant compounds 失效
    脑靶向低分子量疏水性抗氧化剂

    公开(公告)号：US06420429B1

    公开(公告)日：2002-07-16

    申请号：US09322980

    申请日：1999-06-01

    申请人： Daphne Atlas ,  Eldad Melamed ,  Daniel Offen

    发明人： Daphne Atlas ,  Eldad Melamed ,  Daniel Offen

    IPC分类号： A61K31165

    CPC分类号： A61K31/16

    摘要： Novel brain targeted low molecular weight, hydrophobic antioxidants and use of antioxidants in treatment of central nervous system neurodegenerative disorders such as Parkinson's, Alzheimer's and Creutzfeldt-Jakob's diseases and in treatment of conditions of peripheral tissues, such as acute respiratory distress syndrome, amyotrophic lateral sclerosis, atheroscierotic cardiovascular disease and multiple organ dysfunction, in which oxidants are overproduced.

    摘要翻译： 靶向低分子量，疏水性抗氧化剂和抗氧化剂用于治疗中枢神经系统神经退行性疾病如帕金森病，阿尔茨海默病和克雅氏病以及治疗周围组织病症如急性呼吸窘迫综合征，肌萎缩性侧索硬化症 ，动脉粥样硬化心血管疾病和多器官功能障碍，其中氧化剂过量产生。

    Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity
    7.
    发明授权
    Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity 失效
    芳基取代的丙烯酰胺与白三烯B4（LTB-4）受体拮抗剂活性

    公开(公告)号：US06291530B1

    公开(公告)日：2001-09-18

    申请号：US09269251

    申请日：1999-03-23

    申请人： Paul David Greenspan ,  Roger Aki Fujimoto

    发明人： Paul David Greenspan ,  Roger Aki Fujimoto

    IPC分类号： A61K31165

    CPC分类号： C07D213/69 ,  C07C235/34 ,  C07C317/46 ,  C07C323/62 ,  C07D333/16 ,  C07D333/24

    摘要： Disclosed are compounds of formula (I) wherein W is CH or N; R is (mono- or di cabocyclic or heterocyclic aryl)-lower alkyl; R1 is hydrogen or lower alkyl; R2 and R3 are hydrogen, lower alkyl, lower alkoxy-lower alkyl or aryl-lower alkyl; or R2 and R3 joined together represent lower alkylene optionally interrupted by O, NH, N-lower alkyl or S so as to form a ring with the amide nitrogen; X is O, S, SO, S2 or a direct bond; X1 is O, S, SO, SO2 or a direct bond; Y is a direct bond, lower alkylene or lower alkylidene; and Z is carboxyl, 5-tetrazolyl,, hydroxymethyl or carboxyl derivatized in the form of a pharmaceutically acceptable ester, and pharmaceutically acceptable salts thereof; which arm useful as LTB-4 antagonists.

    摘要翻译： 公开了式（I）的化合物，其中W是CH或N; R是（单或二环或环杂环芳基） - 低级烷基; R1是氢或低级烷基; R2和R3是氢，低级烷基，低级烷氧基 - 低级烷基或芳基 - 低级烷基; 或者R 2和R 3连接在一起代表被O，NH，N-低级烷基或S任意中断的低级亚烷基，以便与酰胺氮形成环; X是O，S，SO，S2或直接键; X1是O，S，SO，SO2或直接键; Y是直接键，低级亚烷基或低级亚烷基; Z为羧基，以药学上可接受的酯形式衍生的5-四唑基，羟甲基或羧基，及其药学上可接受的盐; 该臂可用作LTB-4拮抗剂。

    4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
    8.
    发明授权
    4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical 有权
    4-氟-N-茚满-2-基苯甲酰胺及其作为药物的用途

    公开(公告)号：US06812253B2

    公开(公告)日：2004-11-02

    申请号：US10623775

    申请日：2003-07-22

    申请人： Paulus Wohlfart ,  Teri Suzuki ,  Ramalinga M. Dharanipragada ,  Alena Safarova ,  Armin Walser ,  Hartmut Strobel

    发明人： Paulus Wohlfart ,  Teri Suzuki ,  Ramalinga M. Dharanipragada ,  Alena Safarova ,  Armin Walser ,  Hartmut Strobel

    IPC分类号： A61K31165

    CPC分类号： C07C233/65 ,  A61K31/166 ,  C07C2602/08

    摘要： The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) to the said mammal. Compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease PAOD, atherosclerosis, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives, the therapy and prophylaxis of diabetes and diabetes complications (nephropathy, retinopathy), angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, restricted memory performance or a restricted ability to learn.

    摘要翻译： 本发明涉及刺激哺乳动物内皮细胞NO合成酶表达的方法，该方法包括将生理活性量的式（I）的4-氟-N-茚满-2-基苯甲酰胺给予 哺乳动物说 化合物（I）可用于治疗和预防心血管疾病如稳定和不稳定性心绞痛，Prinzmetal心绞痛（痉挛），急性冠状动脉综合征，心力衰竭，心肌梗塞，中风，血栓形成，外周动脉闭塞性疾病PAOD，动脉粥样硬化， PTCA后的再狭窄，内皮损伤，原发性高血压，肺动脉高压，继发性高血压，肾血管性慢性肾小球肾炎，勃起功能障碍，室性心律失常，以及降低绝经后妇女心血管危险或摄入避孕药后，治疗和预防糖尿病和糖尿病并发症 （肾病，视网膜病变），血管发生，支气管哮喘，慢性肾功能衰竭，肝硬化，受限的记忆力或受限的学习能力。

    Angiogenesis inhibitors
    9.
    发明授权
    Angiogenesis inhibitors 有权

    公开(公告)号：US06444705B1

    公开(公告)日：2002-09-03

    申请号：US09823360

    申请日：2001-03-30

    申请人： Shiro Mita ,  Hidehito Matsuoka

    发明人： Shiro Mita ,  Hidehito Matsuoka

    IPC分类号： A61K31165

    摘要： A method for inhibiting angiogenesis comprising administering to a patient (mammal, such as a human) in need thereof, a pharmaceutically effective amount of an angiogenesis inhibitor containing a compound of formula (I) or a pharmaceutically acceptable salt thereof, either alone or in combination with a pharmaceutically acceptable carrier. The method of treatment may be used to treat diseases in which the angiogenesis participates, particularly retinal diseases such as diabetic retinopathy, macular degeneration, retinal vein occlusion and retinal artery occlusion, neovascular glaucoma and tumors such as hemangioma.